Anti-Lewis X Antibody

<strong>Anti-Lewis X Antibody </strong>_x000D_ <strong>Catalog number:</strong> B2014998_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20° C_x000D_ <strong>Keywords:</strong> Anti-Lewis X Monoclonal Antibody_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Testa L, Mano M, Arai RJ, Bonadio RC, Serrano SV, Zorzetto MMC, Crocamo S, Smaletz O, Freitas-Junior R, Hoff PM. Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy Clinics (Sao Paulo). 2021 Oct 11;76:e3146._x000D_ 2: Noble P, Spendlove I, Harding S, Parsons T, Durrant LG. Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29 PLoS One. 2013;8(2):e54892._x000D_ 3: Smaletz O, Ismael G, Del Pilar Estevez-Diz M, Nascimento ILO, de Morais ALG, Cunha-Junior GF, Azevedo SJ, Alves VA, Moro AM, Yeda FP, Dos Santos ML, Majumder I, Hoffman EW. Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission Int J Gynecol Cancer. 2021 Apr;31(4):562-568._x000D_ 4: Smaletz O, Diz MD, do Carmo CC, Sabbaga J, Cunha-Junior GF, Azevedo SJ, Maluf FC, Barrios CH, Costa RL, Fontana AG, Madrigal V, Wainstein AJ, Yeda FP, Alves VA, Moro AM, Blasbalg R, Scott AM, Hoffman EW. A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma Gynecol Oncol. 2015 Aug;138(2):272-7._x000D_ 5: Lövqvist A, Humm JL, Sheikh A, Finn RD, Koziorowski J, Ruan S, Pentlow KS, Jungbluth A, Welt S, Lee FT, Brechbiel MW, Larson SM. PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels J Nucl Med. 2001 Aug;42(8):1281-7._x000D_ 6: Murali R, Kieber-Emmons T. Molecular recognition of a peptide mimic of the Lewis Y antigen by an anti-Lewis Y antibody J Mol Recognit. 1997 Nov-Dec;10(6):269-76._x000D_ 7: Kelly MP, Lee FT, Smyth FE, Brechbiel MW, Scott AM. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model J Nucl Med. 2006 Apr;47(4):716-25._x000D_ 8: Scott AM, Geleick D, Rubira M, Clarke K, Nice EC, Smyth FE, Stockert E, Richards EC, Carr FJ, Harris WJ, Armour KL, Rood J, Kypridis A, Kronina V, Murphy R, Lee FT, Liu Z, Kitamura K, Ritter G, Laughton K, Hoffman E, Burgess AW, Old LJ. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors Cancer Res. 2000 Jun 15;60(12):3254-61._x000D_ 9: Appelmelk BJ, Vandenbroucke-Grauls CMJE. Lipopolysaccharide Lewis Antigens In: Mobley HLT, Mendz GL, Hazell SL, editors. Helicobacter pylori: Physiology and Genetics. Washington (DC): ASM Press; 2001. Chapter 35._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/1972718">10: Hirashima K, Zenita K, Takada A, Kitahara A, Ishihara G, Harada R, Ohmori K, Hirohashi S, Kyoizumi S, Akiyama M, et al. High idiotypic connectivity of the VH7183-encoded antibodies directed to a murine embryonic carbohydrate antigen, Lewis Y, as ascertained by syngenic anti-idiotype monoclonal antibodies J Immunol. 1990 Jul 1;145(1):224-32.</a>_x000D_ _x000D_ <strong>Products Related to Anti-Lewis X Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>